Thoracoscopy in Patients With Stage IIIA Non-Small Cell Lung Cancer
RATIONALE: Diagnostic procedures such as thoracoscopy may help to measure a patient's response to previous treatment.
PURPOSE: Diagnostic trial to determine the accuracy of thoracoscopy in patients who have stage IIIA non-small cell lung cancer.
|Study Design:||Intervention Model: Single Group Assignment
Primary Purpose: Diagnostic
|Official Title:||Pre-Resection Minimally Invasive Surgical Restaging of Stage III (Mediastinal Node Positive) Non-Small Cell Lung Cancer (NSCLC)|
|Study Start Date:||September 1998|
|Study Completion Date:||March 2006|
|Primary Completion Date:||March 2006 (Final data collection date for primary outcome measure)|
- Evaluate the feasibility of using videothoracoscopy to access and identify residual viable cancer in mediastinal lymph nodes and/or evaluate for other conditions that render patients unresectable (pleural carcinomatosis or T4 primary tumors) following prior mediastinoscopy and a period of neoadjuvant therapy in patients with stage IIIA non-small cell lung cancer.
- Evaluate the safety (morbidity and mortality) of preresectional thoracoscopic restaging of these patients.
- Assess the accuracy (false-negative rate) of thoracoscopic mediastinal node restaging in these patients.
OUTLINE: Patients undergo ipsilateral videothoracoscopic evaluation for restaging their disease after prior mediastinoscopy and induction therapy.
Patients with negative restaging procedures are strongly encouraged to undergo anatomic resection (lobectomy, bilobectomy, or pneumonectomy) with complete mediastinal lymphadenectomy.
Patients with a positive restaging procedure may still undergo resection at the discretion of the surgeon and other treating physicians.
PROJECTED ACCRUAL: A total of 75 patients will be accrued for this study within 30 months.